This page sets out the clinical evidence relevant to breast implant illness: what the literature currently supports, what remains unresolved, and how the practice's surgical approach and outcomes data relate to it. Claims are stated conservatively, in line with what the evidence supports.
Breast implant illness (abbreviated BII) refers to a range of systemic symptoms reported by some patients with breast implants in place. It is not a single disease with a defined diagnostic test or established cause, but a pattern of overlapping symptoms. Some patients report improvement following removal of the implants and capsular tissue.
Symptom presentation varies between individuals, and not all patients with implants are affected. The symptoms most commonly reported are set out below.
Persistent exhaustion that rest doesn't resolve.
Difficulty concentrating, memory lapses, and mental cloudiness.
Aching, stiffness and widespread discomfort without clear injury.
Thinning or shedding that appears without another explanation.
Heightened anxiety, low mood, or changes in mood.
Immune responses resembling autoimmune disease without a firm diagnosis.
Unexplained rashes, itching or sensitivity of the skin.
Frequent illness or a sense of a weakened immune response.
Persistent dryness sometimes reported alongside other symptoms.
These symptoms are non-specific and overlap with a number of other conditions. The presence of some of them does not, on its own, confirm BII; it indicates a presentation that warrants proper clinical investigation.
The principal mechanistic hypothesis for BII is the adjuvant theory. In immunology, an adjuvant is a substance that provokes and amplifies the immune response, the same principle applied in certain vaccines.
The theory proposes that, in susceptible individuals, a breast implant acts as a chronic immune adjuvant. The implant and the capsular tissue that forms around it may maintain the immune system in a persistent, low-grade state of activation. In a predisposed patient, this ongoing stimulation is hypothesized to contribute to the systemic, autoimmune-type symptoms reported.
This remains a hypothesis under active study rather than settled fact. It offers a plausible, mechanism-based account of a consistent clinical pattern, and it is the rationale for removing the implant together with its capsule as part of the surgical approach.
Individual susceptibility appears relevant. Genetics, prior autoimmune tendency, and individual immune biology may each influence which patients develop symptoms, which is why two patients with identical implants can present differently.
The two terms are frequently confused, though the distinction is technically precise. It is a useful basis for questions to any surgeon under consultation.
The implant is removed together with its entire capsule as a single, intact unit, so the capsule is not opened and no capsular tissue is left in place. It is the most complete method of removing an implant and its surrounding capsular tissue, and is Dr. Urzola's preferred approach wherever the tissue safely allows.
The entire capsule is removed, though not necessarily in one continuous piece. Where the capsule is thin, adhered to the chest wall, or closely apposed to vital structures, removing it intact carries a risk of injury; it is therefore removed completely but in sections. The whole capsule is removed in either case.
The practice's standard: Dr. Urzola performs en-bloc removal wherever the anatomy safely allows it, and a total capsulectomy in every other case. Capsular tissue is not left in place. Patient safety determines which technique is used; complete removal of the capsule is the constant. Further detail on the operation is set out on the procedures page.
The medical literature reflects differing views on breast implant illness. Some clinicians remain sceptical that BII constitutes a distinct condition, noting that the symptoms are non-specific, that a definitive diagnostic test does not yet exist, and that large randomised studies are lacking. These are legitimate scientific points, and the practice does not dismiss them.
The practice does not overstate outcomes. It does not represent explant as guaranteed to resolve every symptom, nor does it present a diagnosis the wider field is still defining as settled. Its position is to state plainly what the current evidence does and does not support, and to base surgical recommendations on the individual patient's anatomy and health.
Outcome figures cited on this page are provided for context, not as a guarantee. Surgical recommendations are made on clinical grounds specific to each patient.
Every capsule removed can be sent for formal pathological analysis. The capsular tissue that formed around the implant is examined microscopically, providing a documented record of the tissue removed rather than an assumption.
The practice records and reviews its surgical outcomes. The figures below are drawn from an internal outcomes review of more than 130 en-bloc explant patients.
These internal figures sit alongside a growing body of published literature. Independent cohort studies have reported that approximately 50 to 75% of patients experience improvement in systemic symptoms following explant, a range broadly consistent with the practice's own observations. The evidence base remains at an early stage.
The practice maintains a research collaboration with Dr. Arthur Brawer, a New Jersey rheumatologist whose published work addresses implant-related illness. His research on the mechanisms and manifestations of implant-associated symptoms informs the practice's assessment and counselling of patients.
Figures reflect the practice's internal, patient-reported outcomes at six-month follow-up, alongside published cohort literature. They are provided for context only and are not a guarantee of individual results. Individual results vary.
How en-bloc removal, muscle repair, the U-flap lift and fat transfer actually work.
View procedures →Training, credentials, and the surgical standard applied at the practice.
Meet the team →Direct answers on surgery, travel, costs, and recovery.
Read the FAQ →Submit your history for review by Dr. Urzola. Consultations are confidential and carry no obligation.